Community-acquired pneumonia

Hospital-acquired pneumonia is a new pulmonary infiltrate with clinical signs of infection developing 48 hours or more after admission in a nonintubated patient, driven by gram-negative bacilli and Staphylococcus aureus rather than typical community organisms; empiric therapy is broad-spectrum antipseudomonal coverage started without delay and narrowed at 48 to 72 hours.

Ventilator-associated pneumonia is a new pulmonary infiltrate with clinical signs of infection developing more than 48 hours after endotracheal intubation, driven by gram-negative bacilli and Staphylococcus aureus; empiric antipseudomonal therapy is started immediately from a semiquantitative respiratory culture and paired with ventilator-bundle prevention.

Legionella pneumophila is an intracellular, water-borne gram-negative bacillus causing severe community-acquired pneumonia with prominent gastrointestinal and hepatic features, confirmed by urinary antigen testing and treated with a macrolide or fluoroquinolone rather than a beta-lactam.

Influenza is an acute orthomyxoviral respiratory illness with abrupt fever, myalgia, and cough, driven by an H and N surface glycoprotein antigenicity that drifts yearly (seasonal epidemics) and occasionally shifts (pandemics). Diagnosis is clinical or confirmed by nucleic acid amplification testing, and neuraminidase-inhibitor or endonuclease-inhibitor antiviral therapy started within 48 hours of onset shortens illness and reduces complications in high-risk patients.

COVID-19 is the respiratory illness caused by SARS-CoV-2, a positive-sense RNA coronavirus that binds ACE2 receptors, ranging from asymptomatic infection to hypoxemic pneumonia and acute respiratory distress syndrome. Diagnosis relies on RT-PCR of a nasopharyngeal sample, and hospitalized hypoxemic patients are treated with dexamethasone plus remdesivir, escalating to baricitinib or tocilizumab and thromboprophylaxis.

Empyema is frank pus or a culture/Gram-stain-positive bacterial infection of the pleural space, most often complicating pneumonia, that requires prompt drainage plus antibiotics rather than antibiotics alone.

Pleural effusion is fluid accumulation in the pleural space from an imbalance of hydrostatic/oncotic pressure or increased capillary permeability; Light's criteria separate exudates from transudates, and management treats the underlying cause, with therapeutic thoracentesis, chest tube drainage, or pleurodesis for symptomatic or complicated effusions.

Lung abscess is a necrotic, pus-filled cavity in the lung parenchyma, most often from aspiration of oropharyngeal anaerobes in a patient with impaired airway protection, diagnosed by a cavity with an air-fluid level on imaging and treated with prolonged anaerobe-covering antibiotics plus postural drainage.

ARDS is acute (within 1 week), bilateral, non-cardiogenic hypoxemic respiratory failure from diffuse alveolar damage, diagnosed by the 2012 Berlin criteria and graded by the Pao2/Fio2 ratio. Management is lung-protective ventilation, PEEP titration, early prone positioning for severe disease, conservative fluid strategy, and treatment of the inciting insult.

Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection, identified by an acute rise in SOFA score of 2 points or more in a patient with known or suspected infection. Survival depends on recognizing the pattern early and completing the hour-1 bundle: lactate, blood cultures before antibiotics, broad-spectrum antibiotics such as cefepime 2 g IV every 8 hours, and 30 mL/kg crystalloid for hypotension or a lactate of 4 mmol/L or higher.

Septic shock is the subset of sepsis with hypotension requiring vasopressors to maintain a mean arterial pressure above 65 mm Hg plus a serum lactate above 2 mmol/L despite adequate fluid resuscitation, carrying in-hospital mortality of 40% or higher. Management is a timed sequence: 30 mL/kg crystalloid bolus, blood cultures and broad-spectrum antibiotics within 1 hour, norepinephrine titrated to MAP >=65, and escalation to a second vasopressor and stress-dose hydrocortisone when hypotension persists.

Bronchiectasis is chronic, irreversible bronchial dilation from a cycle of infection, inflammation, and airway destruction, diagnosed by high-resolution CT and managed with airway clearance, treatment of the underlying cause, and antibiotics for exacerbations.

Chronic obstructive pulmonary disease is a persistent, usually progressive airflow obstruction driven mainly by cigarette smoke, confirmed by a postbronchodilator FEV1/forced vital capacity (FVC) ratio below 0.70 and staged by GOLD spirometric grade plus symptom/exacerbation group. Maintenance management is a stepwise ladder of smoking cessation, long-acting bronchodilators, add-on inhaled glucocorticoid, roflumilast, or azithromycin for frequent exacerbators, long-term oxygen for resting hypoxemia, and vaccination, with acute exacerbations managed as a separate protocol.

Pulmonary embolism is thrombus, usually from a lower-extremity deep vein thrombosis, obstructing the pulmonary arterial circulation and causing V/Q mismatch, right ventricular strain, and hypoxemia. Diagnosis follows Wells criteria (with PERC in low-risk patients) to sequence D-dimer, CT pulmonary angiography, and V/Q scanning, and management is risk-stratified anticoagulation escalating to thrombolysis or embolectomy for hemodynamic instability.

Tuberculosis, caused by Mycobacterium tuberculosis, remains a leading global cause of infectious death and presents as latent infection, primary/secondary pulmonary disease, or extrapulmonary and disseminated (miliary) disease. Diagnosis rests on AFB smear, NAAT, and mycobacterial culture (the gold standard), and drug-susceptible active disease is treated with a four-drug regimen (isoniazid, rifampin, pyrazinamide, ethambutol) for 2 months followed by isoniazid plus rifampin for 4 to 7 months.

Lung cancer is the leading cause of cancer death worldwide, split into non-small cell lung cancer (NSCLC, 80% of cases: adenocarcinoma, squamous cell, large cell) and small cell lung cancer (SCLC, 10-15%), both driven overwhelmingly by cigarette smoking. Diagnosis requires tissue histopathology, staging drives treatment (TNM staging for NSCLC, limited versus extensive stage for SCLC), and management ranges from lobectomy in early-stage disease through concurrent chemoradiation and consolidation immunotherapy in locally advanced disease to targeted tyrosine kinase inhibitors, immune checkpoint inhibitors, or platinum-based chemotherapy in metastatic disease.

Acute kidney injury is a sudden rise in serum creatinine or fall in urine output from prerenal, intrinsic, or postrenal causes, defined and staged by KDIGO criteria. Management targets the underlying cause, corrects volume and electrolyte derangements, and escalates to renal replacement therapy for refractory hyperkalemia, acidosis, volume overload, or uremia.

Atrial fibrillation is a supraventricular tachyarrhythmia with disorganized atrial activation and an irregularly irregular ventricular response, the most common sustained arrhythmia and a major cause of stroke. Diagnosis is by ECG showing no discrete P waves with irregular RR intervals, and management addresses rate or rhythm control, stroke prevention by CHA2DS2-VASc-guided anticoagulation, and the underlying cause.

Heart failure is a clinical syndrome of impaired cardiac filling or ejection causing congestion and reduced perfusion, classified by ejection fraction. Diagnosis integrates symptoms, signs, natriuretic peptides, and echocardiography, and treatment of reduced-ejection-fraction disease is quadruple guideline-directed therapy, with device therapy and cause-specific management.